Technology | January 18, 2011

FDA Clears Radiotracer to Evaluate Neurodegenerative Disorders

A normal brain scan with the SPECT imaging agent DaTscan showing normal dopamine transporter (DaT) activity.

January 19, 2011 – The U.S. Food and Drug Administration (FDA) cleared a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes (PS).(1)

GE Healthcare’s DaTscan (ioflupane I 123 Injection) is the first FDA-approved diagnostic imaging agent to help physicians evaluate neurodegenerative movement disorders, such as idiopathic (of unknown cause) Parkinson's disease (PD). DaTscan may be used as an adjunct to other diagnostic evaluations to help differentiate essential tremor from tremor due to PS. DaTscan cannot differentiate between the different types of PS.

“Ioflupane may be an important new imaging agent for physicians in differentiating diseases such as Parkinson’s disease from essential tremor,” said Mark Stacy, M.D., neurologist and director of the Duke Movement Disorders Clinic at Duke University Medical Center in Durham, N.C. “Understanding exactly what you are dealing with is important in selecting the appropriate treatments for patients with movement disorders.”

The FDA's action, following a priority review, marks the approval of the first radiopharmaceutical agent to detect DaT distribution within the brain (dopamine is a brain chemical that is classified as a neurotransmitter and is found in regions of the brain that regulate activities such as movement and emotion(2)). The FDA granted DaTscan priority review due to an unmet clinical need for an imaging agent to assist physicians in managing patients according to their dopaminergic status.

“Currently, movement disorders are diagnosed through clinical examinations, blood tests and neuropsychological evaluations, which are not conclusive and may lead to misdiagnosis,” Stacy said. “A new diagnostic adjunct to existing clinical assessments represents a meaningful contribution to the movement disorders field.”

The FDA's approval of DaTscan was based on two phase 3 clinical trials confirming the efficacy of DaTscan for the visualization of DaT distribution within the striata, an interior part of the brain. These studies, evaluating 284 adult patients with tremor, demonstrated the consistent performance of DaTscan in the visual detection of DaT distribution in the brain when compared with a reference clinical diagnosis.(1)

For more information: www.DaTscan.com

References:
(1) DaTscan (Ioflupane I 123 Injection) prescribing information. GE Healthcare, 2010.
(2) Dopamine. Gale Encyclopedia of Medicine. Farmington Hills, MI: The Gale Group Inc., 2008. http://medical-dictionary.thefreedictionary.com/dopamine. Accessed Oct. 19, 2010.

Related Content

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...